BioPharma Bitez: Verona, Aptinyx, and more!

Happy Friday everybody, welcome to this week’s edition of “BioPharma Bitez.” Top news in the industry as well as one story outside of it. Now, with a new, shinier, backdrop!

So, to kick it off this week, Verona suffered a “phase two failure” for a COPD bronchodilator product. It would have been the first one in the last four decades, but they will continue with other indications because there was some other promising data from it.

Aslan has also suffered a practically poor Phase two gastric cancer product. They were going to shift gears and move towards biliary tract cancer focus with that product. 

Aimmune is now on hold for its application for peanut allergy meds due to the government shutdown. 

Aptinyx has a lead product for CNS disorders which actually failed phase two endpoints as well so; their goal is to redo their phase two by the end of this year. 

And then Amgen and UCB finally got approval for the new osteoporosis product after their second FDA filing and submission for it. 

So, one fun fact out of the industry this week with the “Lunar Rover” on the far side of the moon exploring, they actually had cotton grow on the moon. But then also, as of today, has been found to have died, because the temperature dropped below 52 degrees Celsius obviously killing the plants. So, there may be some potential for future growth on the moon, but they do have to keep it warm.

So, thanks for tuning in for this week’s edition of “BioPharma Bitez,” I look forward to seeing you all next week on another edition of “BioPharma Bitez.”